Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004668
Abstract: Background Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1)… read more here.
Keywords: efficacy; anti ipilimumab; acral melanoma; melanoma ... See more keywords